News

WBB Securities Asset Management Receives Hedgeweek Award For Life Sciences Investing

September 22, 2017

WBB Securities, LLC is pleased to announce that the WBB Asset Management Long/Short Life Science Strategy (LSLSS) was the recipient of Hedgeweek USA’s 2017 Award for Best Event Driven Strategy last night in New York City.

Continue Reading

WBB Securities Acts as Co-Manager in $17 Million Follow-on Financing for T2 Biosystems

September 21, 2017

WBB Securities acted as co-manager to a transaction for T2 Biosystems, Inc., a manufacturer of next generation, rapid diagnostic equipment.

Continue Reading

Gilead-Kite: A New Transformative Deal For Biotech

August 30, 2017

After years of anticipation, the world learned on Monday that Gilead Sciences Inc. will acquire Kite Pharma Inc. for almost $12 billion in cash.

Continue Reading

How Martin Shkreli Used Social Media To Fuel His Short-Selling Shenanigans

July 20, 2017

Over the last several months, someone using the pseudonym “Art Doyle” released online reports — I use the word “reports” loosely — to attack several biotech stocks.

Continue Reading

Why The Street Should Fear The Senate Healthcare Bill

June 22, 2017

As the Republican Senate majority unveiled its draft healthcare bill Thursday, there was a rally in healthcare stocks in anticipation of reduced government regulation.

Continue Reading

WBB Securities Acts as Co-Manager in $40 Million Follow-on Financing for Corium International, Inc.

May 31, 2017

WBB Securities acted as co-manager to a transaction for Corium International, Inc., a commercial stage developer of transdermal healthcare products.

Continue Reading

Why Healthcare Reform Won’t Be Rushed — And It Isn’t Political

April 1, 2017

Republicans learned that they must tread carefully in their plans to replace the ACA as the consequences of their actions will result in significant disruption across the healthcare industry.

Continue Reading

WBB Securities Acts as Financial Advisor to T2 Biosystems for $50 Million Credit Facility

January 5, 2017

WBB Securities acted as financial advisor to T2 Biosystems, Inc., a manufacturer of next generation diagnostic equipment, for a credit facility up to $50 million.

Continue Reading

Trump, Interest Rates, And Biotech Investing In 2017

December 23, 2016

We are heading into 2017 with a great deal of uncertainty, but if President-elect Trump governs the nation as he said he would – unconventionally and unpredictably – we may experience a significant uptick in market volatility as foreign governments and global markets react to America’s new stance in the world.

Continue Reading

Siemens And Northwell Announce Alliance, Enter Big Data Arms Race

December 1, 2016

In an era where a doctor’s office can generate a terabyte of data easily and toasters can speak to refrigerators, we are in an unprecedented age of information and connectivity.

Continue Reading